Table 3A.
Clinical characteristics of patients with primary graft failure at first alloSCT.
| n | Patient gender | Age | DX | Disease status at 1 SCT | Conditioning regimen |
Donor gender |
Donor age | SC Source |
CD34+ cell dose | DSA |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 64 | AML | CR1 | TBF2 | M | 38 | BM | 3.7 | POS |
| 2 | M | 69 | AML | FRONTLINE | TBF1 | M | 41 | BM | 4.2 | NEG |
| 3 | M | 69 | AML | FRONTLINE | TBF1 | F | 33 | BM | 6.8 | POS |
| 4 | M | 73 | MFI | STABLE | TBF1 | M | 46 | BM | 3.8 | NEG |
| 5 | F | 60 | MDS | CR1 | TBF2 | M | 30 | BM | 7.5 | POS |
| 6 | M | 43 | AML | CR1 | TBF3 | M | 0 | CBU | 2.5 | NEG |
| 7 | M | 69 | MDS | STABLE | TBF1 | F | 30 | PBSC | 5.8 | POS |
AML, acute myeloid leukemia; MFI, myelofibrosis; MDS, myelodysplastic syndrome; CR1, first complete remission; TBF3, 3 days of busulfan; TBF2, 2 days of busulfan; TBF1, 1 day of busulfan; BM, bone marrow; PBSC, peripheral blood stem cell; CBU, cord blood unit.